LLY
Eli Lilly and Company
598.09
USD
This page is just a preview of the data found in TrendSpider’s full version
Eli Lilly and Company stock is up 0.06% since 30 days ago. The next earnings date is Feb 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 49 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 9 CALLs, 1 PUT. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 08 Dec 19:20 | 15 Dec, 2023 | 600.00 | 3200 | ||
| 08 Dec 19:22 | 19 Jan, 2024 | 590.00 | 1177 | ||
| 08 Dec 19:56 | 21 Jun, 2024 | 640.00 | 186 | ||
| 08 Dec 19:56 | 17 Jan, 2025 | 400.00 | 403 | ||
| 08 Dec 20:00 | 19 Dec, 2025 | 900.00 | 246 | ||
| 08 Dec 20:16 | 19 Jan, 2024 | 590.00 | 1177 | ||
| 08 Dec 20:23 | 19 Jan, 2024 | 590.00 | 1177 | ||
| 08 Dec 20:42 | 15 Dec, 2023 | 570.00 | 606 | ||
| 08 Dec 20:43 | 15 Dec, 2023 | 610.00 | 1552 | ||
| 08 Dec 21:03 | 15 Dec, 2023 | 600.00 | 506 |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic colorectal cancer, and hepatocellular carcinoma. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic ax
